- IBDEI3GX ; ; 19-NOV-2015
- ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
- Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
- Q Q
- ;;^UTILITY(U,$J,358.3,58331,2)
- ;;=^5004465
- ;;^UTILITY(U,$J,358.3,58332,0)
- ;;=H35.32^^272^2906^28
- ;;^UTILITY(U,$J,358.3,58332,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,58332,1,3,0)
- ;;=3^Exudative Age-Related Macular Degeneration
- ;;^UTILITY(U,$J,358.3,58332,1,4,0)
- ;;=4^H35.32
- ;;^UTILITY(U,$J,358.3,58332,2)
- ;;=^5005648
- ;;^UTILITY(U,$J,358.3,58333,0)
- ;;=H35.023^^272^2906^29
- ;;^UTILITY(U,$J,358.3,58333,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,58333,1,3,0)
- ;;=3^Exudative Retinopathy,Bilateral
- ;;^UTILITY(U,$J,358.3,58333,1,4,0)
- ;;=4^H35.023
- ;;^UTILITY(U,$J,358.3,58333,2)
- ;;=^5005588
- ;;^UTILITY(U,$J,358.3,58334,0)
- ;;=H35.022^^272^2906^30
- ;;^UTILITY(U,$J,358.3,58334,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,58334,1,3,0)
- ;;=3^Exudative Retinopathy,Left Eye
- ;;^UTILITY(U,$J,358.3,58334,1,4,0)
- ;;=4^H35.022
- ;;^UTILITY(U,$J,358.3,58334,2)
- ;;=^5005587
- ;;^UTILITY(U,$J,358.3,58335,0)
- ;;=H35.021^^272^2906^31
- ;;^UTILITY(U,$J,358.3,58335,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,58335,1,3,0)
- ;;=3^Exudative Retinopathy,Right Eye
- ;;^UTILITY(U,$J,358.3,58335,1,4,0)
- ;;=4^H35.021
- ;;^UTILITY(U,$J,358.3,58335,2)
- ;;=^5005586
- ;;^UTILITY(U,$J,358.3,58336,0)
- ;;=H40.013^^272^2906^32
- ;;^UTILITY(U,$J,358.3,58336,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,58336,1,3,0)
- ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Bilateral
- ;;^UTILITY(U,$J,358.3,58336,1,4,0)
- ;;=4^H40.013
- ;;^UTILITY(U,$J,358.3,58336,2)
- ;;=^5005726
- ;;^UTILITY(U,$J,358.3,58337,0)
- ;;=H40.012^^272^2906^33
- ;;^UTILITY(U,$J,358.3,58337,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,58337,1,3,0)
- ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Left Eye
- ;;^UTILITY(U,$J,358.3,58337,1,4,0)
- ;;=4^H40.012
- ;;^UTILITY(U,$J,358.3,58337,2)
- ;;=^5005725
- ;;^UTILITY(U,$J,358.3,58338,0)
- ;;=H40.011^^272^2906^34
- ;;^UTILITY(U,$J,358.3,58338,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,58338,1,3,0)
- ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Right Eye
- ;;^UTILITY(U,$J,358.3,58338,1,4,0)
- ;;=4^H40.011
- ;;^UTILITY(U,$J,358.3,58338,2)
- ;;=^5005724
- ;;^UTILITY(U,$J,358.3,58339,0)
- ;;=H52.03^^272^2906^41
- ;;^UTILITY(U,$J,358.3,58339,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,58339,1,3,0)
- ;;=3^Hypermetropia,Bilateral
- ;;^UTILITY(U,$J,358.3,58339,1,4,0)
- ;;=4^H52.03
- ;;^UTILITY(U,$J,358.3,58339,2)
- ;;=^5006262
- ;;^UTILITY(U,$J,358.3,58340,0)
- ;;=H52.02^^272^2906^42
- ;;^UTILITY(U,$J,358.3,58340,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,58340,1,3,0)
- ;;=3^Hypermetropia,Left Eye
- ;;^UTILITY(U,$J,358.3,58340,1,4,0)
- ;;=4^H52.02
- ;;^UTILITY(U,$J,358.3,58340,2)
- ;;=^5006261
- ;;^UTILITY(U,$J,358.3,58341,0)
- ;;=H52.01^^272^2906^43
- ;;^UTILITY(U,$J,358.3,58341,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,58341,1,3,0)
- ;;=3^Hypermetropia,Right Eye
- ;;^UTILITY(U,$J,358.3,58341,1,4,0)
- ;;=4^H52.01
- ;;^UTILITY(U,$J,358.3,58341,2)
- ;;=^5006260
- ;;^UTILITY(U,$J,358.3,58342,0)
- ;;=H59.41^^272^2906^44
- ;;^UTILITY(U,$J,358.3,58342,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,58342,1,3,0)
- ;;=3^Inflammation of Postprocedural Bleb,Stage 1
- ;;^UTILITY(U,$J,358.3,58342,1,4,0)
- ;;=4^H59.41
- ;;^UTILITY(U,$J,358.3,58342,2)
- ;;=^5006426
- ;;^UTILITY(U,$J,358.3,58343,0)
- ;;=H59.42^^272^2906^45
- ;;^UTILITY(U,$J,358.3,58343,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,58343,1,3,0)
- ;;=3^Inflammation of Postprocedural Bleb,Stage 2
- ;;^UTILITY(U,$J,358.3,58343,1,4,0)
- ;;=4^H59.42
- ;;^UTILITY(U,$J,358.3,58343,2)
- ;;=^5006427
- ;;^UTILITY(U,$J,358.3,58344,0)
- ;;=H59.43^^272^2906^46
- ;;^UTILITY(U,$J,358.3,58344,1,0)
- ;;=^358.31IA^4^2
- --- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI3GX 3980 printed Jan 18, 2025@03:49:44 Page 2
- IBDEI3GX ; ; 19-NOV-2015
- +1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
- +2 if 'DIFQR(358.3)
- QUIT
- FOR I=1:2
- SET X=$TEXT(Q+I)
- if X=""
- QUIT
- SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
- SET X=$EXTRACT(X,4,999)
- if $ASCII(Y)=126
- SET I=I+1
- SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,99)
- if $ASCII(Y)=61
- SET Y=$EXTRACT(Y,2,999)
- XECUTE NO
- IF '$TEST
- SET @X=Y
- Q QUIT
- +1 ;;^UTILITY(U,$J,358.3,58331,2)
- +2 ;;=^5004465
- +3 ;;^UTILITY(U,$J,358.3,58332,0)
- +4 ;;=H35.32^^272^2906^28
- +5 ;;^UTILITY(U,$J,358.3,58332,1,0)
- +6 ;;=^358.31IA^4^2
- +7 ;;^UTILITY(U,$J,358.3,58332,1,3,0)
- +8 ;;=3^Exudative Age-Related Macular Degeneration
- +9 ;;^UTILITY(U,$J,358.3,58332,1,4,0)
- +10 ;;=4^H35.32
- +11 ;;^UTILITY(U,$J,358.3,58332,2)
- +12 ;;=^5005648
- +13 ;;^UTILITY(U,$J,358.3,58333,0)
- +14 ;;=H35.023^^272^2906^29
- +15 ;;^UTILITY(U,$J,358.3,58333,1,0)
- +16 ;;=^358.31IA^4^2
- +17 ;;^UTILITY(U,$J,358.3,58333,1,3,0)
- +18 ;;=3^Exudative Retinopathy,Bilateral
- +19 ;;^UTILITY(U,$J,358.3,58333,1,4,0)
- +20 ;;=4^H35.023
- +21 ;;^UTILITY(U,$J,358.3,58333,2)
- +22 ;;=^5005588
- +23 ;;^UTILITY(U,$J,358.3,58334,0)
- +24 ;;=H35.022^^272^2906^30
- +25 ;;^UTILITY(U,$J,358.3,58334,1,0)
- +26 ;;=^358.31IA^4^2
- +27 ;;^UTILITY(U,$J,358.3,58334,1,3,0)
- +28 ;;=3^Exudative Retinopathy,Left Eye
- +29 ;;^UTILITY(U,$J,358.3,58334,1,4,0)
- +30 ;;=4^H35.022
- +31 ;;^UTILITY(U,$J,358.3,58334,2)
- +32 ;;=^5005587
- +33 ;;^UTILITY(U,$J,358.3,58335,0)
- +34 ;;=H35.021^^272^2906^31
- +35 ;;^UTILITY(U,$J,358.3,58335,1,0)
- +36 ;;=^358.31IA^4^2
- +37 ;;^UTILITY(U,$J,358.3,58335,1,3,0)
- +38 ;;=3^Exudative Retinopathy,Right Eye
- +39 ;;^UTILITY(U,$J,358.3,58335,1,4,0)
- +40 ;;=4^H35.021
- +41 ;;^UTILITY(U,$J,358.3,58335,2)
- +42 ;;=^5005586
- +43 ;;^UTILITY(U,$J,358.3,58336,0)
- +44 ;;=H40.013^^272^2906^32
- +45 ;;^UTILITY(U,$J,358.3,58336,1,0)
- +46 ;;=^358.31IA^4^2
- +47 ;;^UTILITY(U,$J,358.3,58336,1,3,0)
- +48 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Bilateral
- +49 ;;^UTILITY(U,$J,358.3,58336,1,4,0)
- +50 ;;=4^H40.013
- +51 ;;^UTILITY(U,$J,358.3,58336,2)
- +52 ;;=^5005726
- +53 ;;^UTILITY(U,$J,358.3,58337,0)
- +54 ;;=H40.012^^272^2906^33
- +55 ;;^UTILITY(U,$J,358.3,58337,1,0)
- +56 ;;=^358.31IA^4^2
- +57 ;;^UTILITY(U,$J,358.3,58337,1,3,0)
- +58 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Left Eye
- +59 ;;^UTILITY(U,$J,358.3,58337,1,4,0)
- +60 ;;=4^H40.012
- +61 ;;^UTILITY(U,$J,358.3,58337,2)
- +62 ;;=^5005725
- +63 ;;^UTILITY(U,$J,358.3,58338,0)
- +64 ;;=H40.011^^272^2906^34
- +65 ;;^UTILITY(U,$J,358.3,58338,1,0)
- +66 ;;=^358.31IA^4^2
- +67 ;;^UTILITY(U,$J,358.3,58338,1,3,0)
- +68 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Right Eye
- +69 ;;^UTILITY(U,$J,358.3,58338,1,4,0)
- +70 ;;=4^H40.011
- +71 ;;^UTILITY(U,$J,358.3,58338,2)
- +72 ;;=^5005724
- +73 ;;^UTILITY(U,$J,358.3,58339,0)
- +74 ;;=H52.03^^272^2906^41
- +75 ;;^UTILITY(U,$J,358.3,58339,1,0)
- +76 ;;=^358.31IA^4^2
- +77 ;;^UTILITY(U,$J,358.3,58339,1,3,0)
- +78 ;;=3^Hypermetropia,Bilateral
- +79 ;;^UTILITY(U,$J,358.3,58339,1,4,0)
- +80 ;;=4^H52.03
- +81 ;;^UTILITY(U,$J,358.3,58339,2)
- +82 ;;=^5006262
- +83 ;;^UTILITY(U,$J,358.3,58340,0)
- +84 ;;=H52.02^^272^2906^42
- +85 ;;^UTILITY(U,$J,358.3,58340,1,0)
- +86 ;;=^358.31IA^4^2
- +87 ;;^UTILITY(U,$J,358.3,58340,1,3,0)
- +88 ;;=3^Hypermetropia,Left Eye
- +89 ;;^UTILITY(U,$J,358.3,58340,1,4,0)
- +90 ;;=4^H52.02
- +91 ;;^UTILITY(U,$J,358.3,58340,2)
- +92 ;;=^5006261
- +93 ;;^UTILITY(U,$J,358.3,58341,0)
- +94 ;;=H52.01^^272^2906^43
- +95 ;;^UTILITY(U,$J,358.3,58341,1,0)
- +96 ;;=^358.31IA^4^2
- +97 ;;^UTILITY(U,$J,358.3,58341,1,3,0)
- +98 ;;=3^Hypermetropia,Right Eye
- +99 ;;^UTILITY(U,$J,358.3,58341,1,4,0)
- +100 ;;=4^H52.01
- +101 ;;^UTILITY(U,$J,358.3,58341,2)
- +102 ;;=^5006260
- +103 ;;^UTILITY(U,$J,358.3,58342,0)
- +104 ;;=H59.41^^272^2906^44
- +105 ;;^UTILITY(U,$J,358.3,58342,1,0)
- +106 ;;=^358.31IA^4^2
- +107 ;;^UTILITY(U,$J,358.3,58342,1,3,0)
- +108 ;;=3^Inflammation of Postprocedural Bleb,Stage 1
- +109 ;;^UTILITY(U,$J,358.3,58342,1,4,0)
- +110 ;;=4^H59.41
- +111 ;;^UTILITY(U,$J,358.3,58342,2)
- +112 ;;=^5006426
- +113 ;;^UTILITY(U,$J,358.3,58343,0)
- +114 ;;=H59.42^^272^2906^45
- +115 ;;^UTILITY(U,$J,358.3,58343,1,0)
- +116 ;;=^358.31IA^4^2
- +117 ;;^UTILITY(U,$J,358.3,58343,1,3,0)
- +118 ;;=3^Inflammation of Postprocedural Bleb,Stage 2
- +119 ;;^UTILITY(U,$J,358.3,58343,1,4,0)
- +120 ;;=4^H59.42
- +121 ;;^UTILITY(U,$J,358.3,58343,2)
- +122 ;;=^5006427
- +123 ;;^UTILITY(U,$J,358.3,58344,0)
- +124 ;;=H59.43^^272^2906^46
- +125 ;;^UTILITY(U,$J,358.3,58344,1,0)
- +126 ;;=^358.31IA^4^2